Currently out of the existing stock ratings of Liisa Bayko, 130 are a BUY (88.44%), 17 are a HOLD (11.56%).

Liisa Bayko

Work Performance Price Targets & Ratings Chart

Analyst Liisa Bayko, currently employed at EVERCORE, carries an average stock price target met ratio of 48.34% that have a potential upside of 53.28% achieved within 275 days.

Liisa Bayko’s has documented 310 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VRTX, Vertex Pharmaceuticals at 23-Jan-2026.

Wall Street Analyst Liisa Bayko

Analyst best performing recommendations are on ENTA (ENANTA PHARMACEUTICALS).
The best stock recommendation documented was for ENTA (ENANTA PHARMACEUTICALS) at 9/15/2025. The price target of $12 was fulfilled within 14 days with a profit of $4.54 (60.86%) receiving and performance score of 43.47.

Average potential price target upside

of $71.65 (63.8%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $32.24 (61.46%) on FSTX (FSTAR THERAPEUTICS).
of $32.24 (61.46%) on SBPH (SPRING BANK PHARMACEUTICALS).

ABUS Arbutus Biopharma Corp AIMT Aimmune Therapeutics BCRX BioCryst Pharmaceuticals CRSP Crispr Therapeutics AG ENTA Enanta Pharmaceuticals ICPT Intercept Pharmaceuticals INSM Insmed KNSA Kiniksa Pharmaceuticals Ltd RARE Ultragenyx SRPT Sarepta Therapeutics ACHN Achillion Pharmaceuticals EDIT Editas Medicine INCY yte MDGL Madrigal Pharmaceuticals TVTX Travere Therapeutics VRTX Vertex Pharmaceuticals PRQR ProQR Therapeutics BV AKRO Akero Therapeutics ALT Altimmune AURA Aura Biosciences CNCE Concert Pharmaceuticals CRBP Corbus Pharmaceuticals RTRX Travere Therapeutics VERA Vera Therapeutics ANTX AN2 Therapeutics ALNY Alnylam Pharmaceuticals AVTE Aerovate Therapeutics ETNB 89bio SVRA Savara FSTX FStar Therapeutics SBPH Spring Bank Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Keay Nakae (CHARDAN CAPITAL)